City Therapeutics closed a $99.5 million Series B financing to advance its RNA interference pipeline and fund expansion of its next-generation RNAi engineering platform. The company said it will use the proceeds to support clinical development of its first three candidates and broaden target discovery beyond liver applications. Founded by former Alnylam executives, City’s positioning reflects ongoing investor emphasis on repeatable RNAi performance and platform scalability, particularly as delivery remains a core challenge for the modality. For the sector, the funding adds to the capital pool supporting RNAi leaders and helps sustain development velocity as companies race to differentiate chemistry, delivery, and tolerability profiles in the clinic.